Non-Indexed GFR: Clinical Significance and When to Use
Non-indexed (absolute) GFR should be used for medication dosing decisions, particularly in patients with extreme body sizes (BSA <1.60 m² or >2.0 m²), as indexed GFR systematically underestimates kidney function in overweight/obese patients and overestimates it in underweight patients, leading to inappropriate drug dosing.
Why Non-Indexed GFR Matters
The standard practice of indexing GFR to body surface area (BSA) of 1.73 m² creates significant clinical problems in patients whose body size deviates from this "average" reference point. The NKF-ASN Task Force explicitly supports deindexing GFR for medication dosing based on compiled data from nine studies showing systematic bias 1.
Magnitude of the Problem
In patients with high BSA (>2.0 m²), indexed eGFR underestimates actual GFR by an average of 19.7-20.9 mL/min depending on the equation used 1. Conversely, in patients with BSA <1.60 m², indexed GFR overestimates actual function by approximately 10 mL/min (11.5%) 2.
This creates a dangerous situation:
- Overweight/obese patients: Risk medication underdosing, potentially leading to treatment failure (especially critical for chemotherapy and antibiotics)
- Underweight patients: Risk medication overdosing and toxicity
When to Use Non-Indexed GFR
Mandatory Situations
Medication dosing for renally excreted drugs - This is the primary indication 1
- Chemotherapy agents (where underdosing may decrease survival) 1
- Antibiotics
- Anticoagulants
- Any narrow therapeutic index drug eliminated by kidneys
Patients with BMI >35 - Half of these patients have clinically significant changes in eGFR when deindexed, often improving by an entire CKD stage 3
Patients with BSA extremes:
- BSA <1.60 m²
- BSA >2.0 m²
How to Calculate Non-Indexed GFR
Take the laboratory-reported indexed eGFR (mL/min/1.73 m²) and multiply by the patient's actual BSA, then divide by 1.73:
Non-indexed GFR = (indexed eGFR × patient's BSA) / 1.73
Clinical Algorithm
Step 1: Calculate patient's BSA using standard formulas (Mosteller or DuBois)
Step 2: Determine if deindexing is needed:
- BMI >35? → Deindex
- BSA <1.60 m² or >2.0 m²? → Deindex
- Prescribing renally excreted medications with narrow therapeutic windows? → Deindex
Step 3: Use the deindexed value for medication dosing calculations
Step 4: Continue using indexed GFR for CKD staging and diagnosis
Critical Caveats
What NOT to Use Non-Indexed GFR For
Keep using indexed GFR (mL/min/1.73 m²) for:
- CKD diagnosis and staging 4
- Determining eligibility for kidney-protective medications (SGLT2 inhibitors, ACE inhibitors/ARBs)
- Clinical trial enrollment criteria
- Tracking disease progression over time
The KDIGO 2024 guidelines maintain that indexed GFR remains the standard for defining and staging CKD 4.
Special Populations
Obesity and racial disparities: This issue disproportionately affects Black adults, particularly Black women, who have the highest obesity prevalence in the United States. Using indexed eGFR in these patients can exacerbate medication dosing disparities 1.
Children: In obese children, consider normalizing to ideal body weight-derived BSA rather than actual BSA to avoid overcorrection 5.
The Pharmacist's Approach
Pharmacists have long recognized this problem and routinely adjust the Cockcroft-Gault equation using different body weights (ideal, adjusted, or total) depending on patient characteristics 1. This individualized approach should be extended to all GFR-based medication dosing decisions.
Bottom Line for Practice
For medication dosing: Calculate and use non-indexed GFR in patients with extreme body sizes (BMI >35 or BSA outside 1.60-2.0 m²). This prevents systematic underdosing in obese patients and overdosing in underweight patients.
For everything else: Continue using standard indexed eGFR (mL/min/1.73 m²) for CKD diagnosis, staging, and determining eligibility for kidney-protective therapies.